Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?

Antibody–Drug Conjugates (ADCs) have been through multiple cycles of technological innovation since the concept was first practically demonstrated ~40 years ago. Current technology is focusing on large, whole immunoglobulin formats (of which there are approaching 100 in clinical development), many w...

Descripción completa

Detalles Bibliográficos
Autores principales: Deonarain, Mahendra P., Yahioglu, Gokhan, Stamati, Ioanna, Pomowski, Anja, Clarke, James, Edwards, Bryan M., Diez-Posada, Soraya, Stewart, Ashleigh C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698822/
https://www.ncbi.nlm.nih.gov/pubmed/31544868
http://dx.doi.org/10.3390/antib7020016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698822/
https://www.ncbi.nlm.nih.gov/pubmed/31544868
http://dx.doi.org/10.3390/antib7020016

Ejemplares similares